Sign In
Buy AFMD
$0.182
+0 (+0%)
At Close: Sep 16, 2025
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
01:05pm, Monday, 07'th Nov 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Tops Revenue Estimates
12:45pm, Monday, 07'th Nov 2022 Zacks Investment Research
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -20% and 51.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Best Penny Stocks To Buy? 5 To Watch For November 2022
10:58am, Monday, 07'th Nov 2022
Penny stocks to watch this week. The post Best Penny Stocks To Buy?
Why Starbucks Shares Are Trading Higher; Here Are 43 Stocks Moving Premarket
12:35pm, Friday, 04'th Nov 2022 Benzinga
Gainers
Sentage Holdings Inc. (NASDAQ: SNTG) shares rose 67.7% to $5.10 in pre-market trading after jumping 24% on Thursday.
BioAtla, Inc. (NASDAQ: BCAB) rose 47.5% to $9.38 in pre-market trading aft
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
10:30am, Friday, 04'th Nov 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
06:30am, Friday, 04'th Nov 2022
HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back the
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
01:15pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
HEIDELBERG, Germany and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”), and Artiva Biotherapeutics Inc. (“Artiva”), both immuno-oncology companies focus
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting
01:05pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t
Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
09:45pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.11% and 8.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Affimed to Present at the 2022 Jefferies London Healthcare Conference
10:30am, Tuesday, 01'st Nov 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t
Affimed to Present at the 2022 Jefferies London Healthcare Conference
06:30am, Tuesday, 01'st Nov 2022
HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back the
Affimed: Data Readout Of AFM13 This Quarter Could Push Company Forward
04:16am, Wednesday, 26'th Oct 2022
Two poster presentations showing AFM24 as a monotherapy and combination treatment will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, November 8-12, 2022. Results
Why Affimed Stock Plummeted by Over 16% Today
10:42pm, Monday, 10'th Oct 2022 The Motley Fool
An analyst's downgrade brings out the bears for the European cancer treatment developer.
Why Affimed Stock Plummeted by Over 16% Today
06:42pm, Monday, 10'th Oct 2022
An analyst's downgrade brings out the bears for the European cancer treatment developer.
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
02:08pm, Monday, 10'th Oct 2022 Benzinga
Upgrades
OTR Global upgraded the previous rating for Restaurant Brands International Inc (NYSE:QSR) from Mixed to Positive. For the second quarter, Restaurant Brands Intl had an EPS of $0.82, compared
